Presentation is loading. Please wait.

Presentation is loading. Please wait.

Page 1 Social and socio-economic benefits of antiretroviral therapy adherence among HIV-infected people who use illicit drugs in Vancouver, Canada Lindsey.

Published byAllyson Holland Modified over 8 years ago

Similar presentations

Presentation on theme: "Page 1 Social and socio-economic benefits of antiretroviral therapy adherence among HIV-infected people who use illicit drugs in Vancouver, Canada Lindsey."— Presentation transcript:

1 Page 1 Social and socio-economic benefits of antiretroviral therapy adherence among HIV-infected people who use illicit drugs in Vancouver, Canada Lindsey Richardson, Thomas Kerr, Robert Hogg, Sylivia Guillemi, Julio Montaner, Evan Wood and M-J Milloy British Columbia Centre for Excellence in HIV/AIDS 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention Vancouver, 21 July 2015

2 Page 2 I have no conflicts of interest to declare Conflict of interest declaration

3 Page 3 Non-detectable viral load, stalled disease progression, reduced comorbidities Life expectancy approaches non-HIV+ for people optimally maintained on ART Sustained and significant population-level decreases in onward HIV transmission from ART scale up (TasP) Analogous benefits for people who use illicit drugs (PWUD) What about secondary clinical and non- clinical benefits of ART? Background Background: Clinical benefits of ART adherence Nosyk et al. (2013) Lancet ID; Montaner et al., (2014) Plos One

4 Page 4 Study objective: To examine whether becoming optimally adherent to ART is associated with improvements in a range of social, socio-economic and secondary clinical outcomes among people who use illicit drugs

5 Page 5 AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS) Design: Community-recruited cohort of people living with HIV/AIDS who use illicit drugs (ongoing since 1996) Data: Interviewer administered questionnaire and blood sample for serologic analysis at baseline and semi-annually Data linkages: Complete retrospective and prospective HIV clinical profile including all VL and ART dispensation from provincial treatment provider (BCCfE Drug Treatment Program) Methods: -Generalized linear mixed effects models for each outcome -Backwards model selection with adjustment for known/hypothesized confounders Data and Methods

6 Page 6 Outcome Measures Entering employment Ceasing involvement in prohibited income generation ≥95% adherence to ART Intimate relationship initiation Transitioning out of homelessness Addiction treatment enrollment Outcomes and Measures:

7 Page 7 Results: Sample and Baseline Characteristics Results (1)

8 Page 8 Results: Social/Socio-economic outcomes and adherence Results (2)

9 Page 9 Conclusions: Conclusions ART adherence increases the likelihood of reducing socio-economic vulnerability: -Ceasing prohibited income generation -Transitioning out of homelessness Improved socio-economic well-being can reinforce engagement in HIV care, quality of life and individual health outcomes Clinical and non-clinical importance of promoting early ART uptake for all in support of UNAIDS 90-90-90 targets

10 Page 10 Acknowledgements All study participants who provide their time and expertise Co-investigators and the research team at the BC-CfE Carmen Rock, Tricia Collingham, Deborah Graham, Peter Vann, Jennifer Matthews and Steve Kain for research and administrative assistance Study support from the US National Institutes of Health (R01DA021525) Canadian Institutes of Health Research, National Institutes of Health and the Michael Smith Foundation for Health Research, for additional research and investigator support

Download ppt "Page 1 Social and socio-economic benefits of antiretroviral therapy adherence among HIV-infected people who use illicit drugs in Vancouver, Canada Lindsey."

Similar presentations

OUR FOCUS: UN POLITICAL DECLARATION TARGET No. 4.

OUR FOCUS: UN POLITICAL DECLARATION TARGET No. 4.
Page 1 Peer-delivered HIV testing and counseling among people who inject drugs in Bangkok, Thailand Lianping Ti 1 Kanna Hayashi 1,2 Karyn Kaplan 3 Paisan.

Page 1 Peer-delivered HIV testing and counseling among people who inject drugs in Bangkok, Thailand Lianping Ti 1 Kanna Hayashi 1,2 Karyn Kaplan 3 Paisan.
Slide 1 of 42 IAS–USA Treatment as Prevention: Evaluating the Impact of HAART Expansion The British Columbia (BC) Experience AU EDITED FINAL: 03-18-13.

Slide 1 of 42 IAS–USA Treatment as Prevention: Evaluating the Impact of HAART Expansion The British Columbia (BC) Experience AU EDITED FINAL:
Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.

Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
Page 1 Use of modest financial incentives to improve engagement of drug users in HIV testing and post- test follow-up: results of a randomized controlled.

Page 1 Use of modest financial incentives to improve engagement of drug users in HIV testing and post- test follow-up: results of a randomized controlled.
THE CORE STUDY COMPARING TWO STRATEGIES FOR ENROLLING HIV-INFECTED PREGNANT WOMEN FROM ANTENATAL CARE TO CARE AND TREATMENT SERVICES IN CAMEROON: CONTINUUM.

THE CORE STUDY COMPARING TWO STRATEGIES FOR ENROLLING HIV-INFECTED PREGNANT WOMEN FROM ANTENATAL CARE TO CARE AND TREATMENT SERVICES IN CAMEROON: CONTINUUM.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.

Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Can we reach UNAIDS 90-90- 90 targets and will this lead to the elimination of HIV in the UK? Dr Valerie Delpech Head of national HIV surveillance.

Can we reach UNAIDS targets and will this lead to the elimination of HIV in the UK? Dr Valerie Delpech Head of national HIV surveillance.
Positive Living Navajo AIDS Network, Inc. Melvin Harrison, Executive Director Marco Arviso, Arizona Medical Case Manager.

Positive Living Navajo AIDS Network, Inc. Melvin Harrison, Executive Director Marco Arviso, Arizona Medical Case Manager.
Community viral load and newly reported HIV infections in Switzerland Matthias Egger Professor of Epidemiology & Public Health Institute of Social and.

Community viral load and newly reported HIV infections in Switzerland Matthias Egger Professor of Epidemiology & Public Health Institute of Social and.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
STOP HIV/AIDS Rolando Barrios, MD, FRCPC Assistant Director BC Centre for Excellence in HIV/AIDS Assistant Medical Director HIV/AIDS Program Providence.

STOP HIV/AIDS Rolando Barrios, MD, FRCPC Assistant Director BC Centre for Excellence in HIV/AIDS Assistant Medical Director HIV/AIDS Program Providence.
Cascade of HIV Care in the Netherlands from 2002 to 2013. Esther Engelhard 14th European AIDS Conference October 18, 2013 Disclosed no conflict of interest.

Cascade of HIV Care in the Netherlands from 2002 to Esther Engelhard 14th European AIDS Conference October 18, 2013 Disclosed no conflict of interest.
The effects of OAT and HAART on the cause-specific risk of mortality among HIV positive people who inject drugs Bohdan Nosyk, PhD Associate Professor,

The effects of OAT and HAART on the cause-specific risk of mortality among HIV positive people who inject drugs Bohdan Nosyk, PhD Associate Professor,
Page 1 HIV Treatment-as-Prevention (TasP) for people who use illicit drugs and implications for HCV TasP: The North American experience M-J MILLOY Research.

Page 1 HIV Treatment-as-Prevention (TasP) for people who use illicit drugs and implications for HCV TasP: The North American experience M-J MILLOY Research.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.

Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.

Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
Baseline Antiretroviral Resistance Testing among HIV-Positive Injection Drug Users in a Canadian Setting Nadia Fairbairn 1 M-J Milloy 1 Thomas Kerr 1,

Baseline Antiretroviral Resistance Testing among HIV-Positive Injection Drug Users in a Canadian Setting Nadia Fairbairn 1 M-J Milloy 1 Thomas Kerr 1,
Www.aids2012.org Washington D.C., USA, JULY 22-27 2012 Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.

Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.

Similar presentations

Ads by Google